Stock Traders Purchase High Volume of Call Options on Core Scientific (NASDAQ:CORZ)

Core Scientific, Inc. (NASDAQ:CORZ) was the target of some unusual options trading activity on Tuesday. Traders acquired 141,404 call options on the stock. This is an increase of approximately 55% compared to the typical volume of 91,193 call options.

Core Scientific Stock Performance

Shares of CORZ traded up $0.01 during midday trading on Tuesday, hitting $20.75. 27,656,519 shares of the stock were exchanged, compared to its average volume of 12,600,461. Core Scientific has a 52-week low of $12.60 and a 52-week high of $30.46. The stock has a fifty day simple moving average of $25.36 and a 200 day simple moving average of $20.74. The firm has a market cap of $6.60 billion, a P/E ratio of -18.20 and a beta of 5.50.

Core Scientific (NASDAQ:CORZ) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($1.04). The company had revenue of $115.24 million during the quarter, compared to analysts’ expectations of $117.04 million. During the same quarter in the previous year, the company earned $1.25 EPS. The company’s revenue for the quarter was up 44.9% on a year-over-year basis. As a group, equities research analysts forecast that Core Scientific will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on CORZ. Keefe, Bruyette & Woods cut Core Scientific from an “outperform” rating to a “market perform” rating and set a $25.00 price objective on the stock. in a report on Monday. Sanford C. Bernstein reissued an “outperform” rating and set a $32.00 target price on shares of Core Scientific in a research note on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Core Scientific in a research report on Friday, July 17th. Loop Capital set a $40.00 price target on Core Scientific in a research note on Friday, June 12th. Finally, Jefferies Financial Group increased their price target on Core Scientific from $24.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.39.

Insider Buying and Selling at Core Scientific

In other news, insider Todd M. Duchene sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $22.30, for a total transaction of $223,000.00. Following the completion of the sale, the insider owned 1,999,101 shares in the company, valued at $44,579,952.30. This trade represents a 0.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 80,000 shares of company stock valued at $2,025,400. Corporate insiders own 1.70% of the company’s stock.

Institutional Trading of Core Scientific

Hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its stake in shares of Core Scientific by 106.1% in the first quarter. AQR Capital Management LLC now owns 283,432 shares of the company’s stock valued at $2,052,000 after purchasing an additional 145,905 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Core Scientific by 180.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,109,387 shares of the company’s stock worth $8,032,000 after buying an additional 714,388 shares during the period. Cetera Investment Advisers increased its stake in Core Scientific by 200.0% during the 2nd quarter. Cetera Investment Advisers now owns 38,819 shares of the company’s stock worth $663,000 after buying an additional 25,878 shares during the period. Franklin Resources Inc. acquired a new stake in Core Scientific during the 2nd quarter worth approximately $181,000. Finally, Russell Investments Group Ltd. lifted its holdings in Core Scientific by 61.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,942 shares of the company’s stock worth $67,000 after buying an additional 1,507 shares in the last quarter.

Core Scientific News Roundup

Here are the key news stories impacting Core Scientific this week:

• Positive Sentiment: AMD partnership creates major AI-infrastructure opportunity: Core Scientific agreed to provide AMD with access to up to 2.5 gigawatts of data-center capacity. The initial 530-megawatt deployment is backed by 15-year agreements across five sites and represents approximately $14 billion in potential base contracted revenue. Core Scientific signs AI infrastructure deal with AMD
• Positive Sentiment: AI transition is already lifting colocation revenue: Second-quarter revenue reached $164.2 million, with colocation revenue reportedly rising to $136.7 million from $10.6 million a year earlier. The company also reported adjusted EBITDA of $41.1 million, highlighting the potential for more stable, recurring revenue compared with cryptocurrency mining. Core Scientific Announces Second Quarter 2026 Results
• Positive Sentiment: Analysts remain bullish: Needham reaffirmed its “buy” rating with a $29 price target, while BTIG reiterated “buy” and maintained a $38 target. The targets reflect confidence that the AI-infrastructure pivot can materially improve Core Scientific’s long-term valuation.
• Positive Sentiment: Options activity signals speculative bullish interest: Investors purchased 141,404 call options Tuesday, 55% above the typical call volume of 91,193 contracts. This does not guarantee further gains, but it indicates elevated expectations for the shares.
• Neutral Sentiment: Adjusted earnings beat, but accounting results were weak: Zacks reported adjusted quarterly EPS of $0.18 versus expectations for a $0.02 loss. Separately, Core Scientific reported a GAAP loss of $3.32 per share, largely reflecting non-cash warrant fair-value adjustments, making the headline earnings result highly volatile.
• Negative Sentiment: Execution, financing and dilution risks remain: Core Scientific spent approximately $797.5 million on capital expenditures during the quarter to convert mining sites for AI workloads. AMD also received warrants to purchase 30 million CORZ shares at $23.47, creating potential dilution if the expansion proceeds.
• Negative Sentiment: Insider selling and a recent downgrade temper enthusiasm: Director Todd M. Duchene sold 10,000 shares for $223,000, while Keefe, Bruyette & Woods downgraded the stock to “market perform,” despite assigning a $25 price target.

About Core Scientific

Core Scientific, Inc (NASDAQ: CORZ) is a leading provider of large-scale blockchain infrastructure and digital asset mining services. The company develops, owns and operates high-performance data centers optimized for the mining of Bitcoin and other proof-of-work cryptocurrencies. In addition to its core mining operations, Core Scientific offers colocation, hosting and managed services designed to support institutional clients and enterprise users in deploying and scaling blockchain nodes and computing hardware.

Core Scientific’s service portfolio includes hardware procurement, deployment and maintenance, real-time monitoring, power management and network connectivity.